VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ALMSAlumis Inc. Common Stock
$23.41$2.9B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

ALMS logoAlumis Inc. Common Stock(ALMS)Earnings, Financials & Key Ratios

ALMS•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryImmunology and Inflammation Therapies
AboutAlumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.Show more
  • Revenue$24M
  • EBITDA-$424M-42.4%
  • Net Income-$243M+17.3%
  • EPS (Diluted)-2.86+72.4%
  • Gross Margin85.46%
  • EBITDA Margin-1761.78%
  • Operating Margin-1776.32%
  • Net Margin-1011.75%
  • ROE-86.69%+23.4%

ALMS Key Insights

Alumis Inc. Common Stock (ALMS) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 96 (top 4%)
  • ✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Shares diluted 100.0% in last year
  • ✗Expensive at 66.1x book value
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when ALMS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ALMS Price & Volume

Alumis Inc. Common Stock (ALMS) stock price & volume — 10-year historical chart

Loading chart...

ALMS Growth Metrics

Alumis Inc. Common Stock (ALMS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM-51.68%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM30.85%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM69.67%

Return on Capital

10 Years-154.26%
5 Years-154.26%
3 Years-165.65%
Last Year-135.9%

ALMS Recent Earnings

Alumis Inc. Common Stock (ALMS) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 3/12 qtrs (38%)●Beat Revenue 2/12 qtrs (33%)
Q2 2026Latest
May 14, 2026
Metric
Actual
Est
EPS
$0.74+0.4%
$0.74
Rev
$2M-15.4%
$2M
Q2 2026
Mar 19, 2026
Metric
Actual
Est
EPS
$0.95+2.1%
$0.97
Rev
$2M-18.4%
$2M
Q4 2025
Nov 13, 2025
Metric
Actual
Est
EPS
$1.06-15.2%
$0.92
Rev
$2M-24.9%
$3M
Q3 2025
Aug 13, 2025
Metric
Actual
Est
EPS
$1.17-5.4%
$1.11
Rev
$3M-15.2%
$3M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 14, 2026
$0.74vs $0.74+0.4%
$2Mvs $2M-15.4%
Q2 2026Mar 19, 2026
$0.95vs $0.97+2.1%
$2Mvs $2M-18.4%
Q4 2025Nov 13, 2025
$1.06vs $0.92-15.2%
$2Mvs $3M-24.9%
Q3 2025Aug 13, 2025
$1.17vs $1.11-5.4%
$3Mvs $3M-15.2%
Based on last 12 quarters of dataView full earnings history →

ALMS Peer Comparison

Alumis Inc. Common Stock (ALMS) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
ABBV logoABBVAbbVie Inc.Direct Competitor383.17B216.6391.418.57%6.91%62.15%
CLDX logoCLDXCelldex Therapeutics, Inc.Direct Competitor2.16B32.43-8.32-78.63%-345.96%-50.72%0.00
ARVN logoARVNArvinas, Inc.Direct Competitor494.88M7.67-5.99-0.3%-247.54%-44.39%0.02
IMVT logoIMVTImmunovant, Inc.Direct Competitor7.26B35.34-12.76-68.16%0.00
VTRS logoVTRSViatris Inc.Direct Competitor17.9B15.37-5.12-2.98%-2.04%-1.97%1.00
PFE logoPFEPfizer Inc.Product Competitor143.46B25.2218.54-1.65%11.83%8.34%0.78
JNJ logoJNJJohnson & JohnsonProduct Competitor550.4B228.3939.454.3%27.26%31.69%0.51
BMY logoBMYBristol-Myers Squibb CompanyProduct Competitor110.25B54.0015.65-0.22%15.01%38.96%2.55

Compare ALMS vs Peers

Alumis Inc. Common Stock (ALMS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ABBV

Most directly comparable listed peer for ALMS.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare ALMS against a more recognizable public peer.

Peer Set

Compare Top 5

vs ABBV, CLDX, ARVN, IMVT

ALMS Income Statement

Alumis Inc. Common Stock (ALMS) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
00024.05M8.4M
Revenue Growth %
-----51.68%
Cost of Goods Sold
250K03.15M3.5M871K
COGS % of Revenue
---14.54%-
Gross Profit
-250K▲ 0%
0▲ 100.0%
-3.15M▲ 0%
20.55M▲ 752.1%
7.53M▲ 0%
Gross Margin %
---85.46%89.63%
Gross Profit Growth %
-100%-752.09%-
Operating Expenses
113.6M158.17M297.6M447.76M458.22M
OpEx % of Revenue
---1861.78%-
Selling, General & Admin
12.55M20.5M35.2M91.86M75.17M
SG&A % of Revenue
---381.94%-
Research & Development
101.05M137.68M265.55M386M370.05M
R&D % of Revenue
---1604.98%-
Other Operating Expenses
00-3.15M-30.1M1000K
Operating Income
-113.85M▲ 0%
-158.17M▼ 38.9%
-300.75M▼ 90.1%
-427.2M▼ 42.0%
-450.69M▲ 0%
Operating Margin %
----1776.32%-5364.02%
Operating Income Growth %
--38.93%-90.14%-42.04%-
EBITDA
-113.6M-156.89M-297.6M-423.71M-447.16M
EBITDA Margin %
----1761.78%-5322.08%
EBITDA Growth %
--38.11%-89.69%-42.37%-27.23%
D&A (Non-Cash Add-back)
250K1.28M3.15M3.5M3.52M
EBIT
-113.85M-158.17M-300.75M-427.2M-430.99M
Net Interest Income
1.99M3.37M12.02M14.18M16.92M
Interest Income
1.99M3.37M12.02M14.18M16.92M
Interest Expense
00000
Other Income/Expense
1.92M3.18M6.52M175.32M204.71M
Pretax Income
-111.93M▲ 0%
-154.99M▼ 38.5%
-294.23M▼ 89.8%
-251.89M▲ 14.4%
-245.98M▲ 0%
Pretax Margin %
----1047.34%-2927.59%
Income Tax
000-8.56M-8.56M
Effective Tax Rate %
0%0%0%3.4%3.48%
Net Income
-111.93M▲ 0%
-154.99M▼ 38.5%
-294.23M▼ 89.8%
-243.32M▲ 17.3%
-237.41M▲ 0%
Net Margin %
----1011.75%-2825.7%
Net Income Growth %
--38.47%-89.84%17.3%30.85%
Net Income (Continuing)
-111.93M-154.99M-294.23M-243.32M-237.41M
Discontinued Operations
00000
Minority Interest
00000
EPS (Diluted)
-14.93▲ 0%
-2.99▲ 80.0%
-10.38▼ 247.2%
-2.86▲ 72.4%
-1.90▲ 0%
EPS Growth %
-79.97%-247.16%72.45%69.67%
EPS (Basic)
-14.93-2.99-10.38-2.86-
Diluted Shares Outstanding
7.5M51.84M28.34M850.3M125.05M
Basic Shares Outstanding
7.5M51.84M28.34M850.3M125.05M
Dividend Payout Ratio
-----

ALMS Balance Sheet

Alumis Inc. Common Stock (ALMS) balance sheet — assets, liabilities & shareholders' equity

MetricDec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
102.56M53.36M306.19M318.23M532.41M
Cash & Short-Term Investments
92.86M48.95M288.26M308.5M522.94M
Cash Only
25.61M46M169.53M89.67M63.88M
Short-Term Investments
67.25M2.96M118.74M218.83M459.06M
Accounts Receivable
500K722K1.81M2.08M2.73M
Days Sales Outstanding
---31.61177.1
Inventory
00000
Days Inventory Outstanding
-----
Other Current Assets
206K208K762K7.65M6.73M
Total Non-Current Assets
5.61M36.26M34.8M93.71M139.18M
Property, Plant & Equipment
4.47M35.22M33.69M35.16M33.49M
Fixed Asset Turnover
---0.68x0.23x
Goodwill
00000
Intangible Assets
00050.96M50.96M
Long-Term Investments
00001.37M
Other Non-Current Assets
1.14M1.03M1.11M7.59M54.74M
Total Assets
108.17M▲ 0%
89.61M▼ 17.2%
340.99M▲ 280.5%
411.94M▲ 20.8%
671.59M▲ 0%
Asset Turnover
---0.06x0.02x
Asset Growth %
--17.15%280.52%20.81%326.5%
Total Current Liabilities
13.35M20.87M50.91M73.32M70.9M
Accounts Payable
1.72M1.12M9.62M10.11M11.59M
Days Payables Outstanding
2.51K-1.11K1.06K4.32K
Short-Term Debt
0004.67M4.44M
Deferred Revenue (Current)
0001.46M7.79M
Other Current Liabilities
3.58M5.58M7.76M57.08M48.55M
Current Ratio
7.68x2.56x6.01x4.34x7.51x
Quick Ratio
7.68x2.56x6.01x4.34x7.51x
Cash Conversion Cycle
-----4.14K
Total Non-Current Liabilities
290.06M408M29.98M37.33M33.66M
Long-Term Debt
00000
Capital Lease Obligations
469K30.86M29.16M32.24M131.57M
Deferred Tax Liabilities
0002.14M8.56M
Other Non-Current Liabilities
289.59M377.14M814K330K301K
Total Liabilities
303.41M428.87M80.89M110.64M104.57M
Total Debt
1.78M32.58M30.72M36.91M35.66M
Net Debt
-23.83M-13.42M-138.8M-52.76M-28.22M
Debt / Equity
--0.12x0.12x0.06x
Debt / EBITDA
-----0.08x
Net Debt / EBITDA
----0.06x
Interest Coverage
-----
Total Equity
-195.24M▲ 0%
-339.26M▼ 73.8%
260.1M▲ 176.7%
301.3M▲ 15.8%
567.02M▲ 0%
Equity Growth %
--73.76%176.67%15.84%473.78%
Book Value per Share
-26.04-6.549.180.354.53
Total Shareholders' Equity
-195.24M-339.26M260.1M301.3M567.02M
Common Stock
1K1K4K9K12K
Retained Earnings
-209.32M-364.32M-658.55M-901.88M-994.93M
Treasury Stock
00000
Accumulated OCI
-127K2K40K188K-467K
Minority Interest
00000

ALMS Cash Flow Statement

Alumis Inc. Common Stock (ALMS) cash flow — operating, investing & free cash flow history

MetricDec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
-107.72M-129.97M-255.08M-369.52M-376.25M
Operating CF Margin %
----1536.48%-
Operating CF Growth %
--20.66%-96.25%-44.87%-140.36%
Net Income
-111.93M-154.99M-294.23M-243.32M-237.41M
Depreciation & Amortization
250K1.28M3.15M3.5M3.52M
Stock-Based Compensation
5.96M8.63M19.46M43.52M9.79M
Deferred Taxes
000-8.56M-8.56M
Other Non-Cash Items
-86K3.05M1.79M-190.97M-152.12M
Working Capital Changes
-1.92M12.06M14.76M26.32M8.53M
Change in Receivables
00000
Change in Inventory
00000
Change in Payables
1.29M-642K8.51M-6.04M-3.44M
Cash from Investing
-68.75M60.47M-113.79M287.88M-37.24M
Capital Expenditures
-2.41M-4.5M-1.73M-653K-780K
CapEx % of Revenue
---2.72%9.28%
Acquisitions
00000
Investments
-----
Other Investing
00049.74M49.74M
Cash from Financing
101.63M89.68M492.37M2.07M349.06M
Debt Issued (Net)
00000
Equity Issued (Net)
99.89M89.78M451.78M2.07M349.07M
Dividends Paid
00000
Share Repurchases
000-17K0
Other Financing
1.73M-96K40.59M0-17K
Net Change in Cash
-74.85M▲ 0%
20.18M▲ 127.0%
123.5M▲ 512.0%
-79.58M▼ 164.4%
-64.58M▲ 0%
Free Cash Flow
-110.13M▲ 0%
-134.47M▼ 22.1%
-256.81M▼ 91.0%
-370.18M▼ 44.1%
-377.03M▲ 0%
FCF Margin %
----1539.19%-4487.38%
FCF Growth %
--22.11%-90.97%-44.14%-28.77%
FCF per Share
-14.69-2.59-9.06-0.44-3.02
FCF Conversion (FCF/Net Income)
0.96x0.84x0.87x1.52x1.59x
Interest Paid
00000
Taxes Paid
00000

ALMS Key Ratios

Alumis Inc. Common Stock (ALMS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric202320242025TTM
Return on Equity (ROE)
--113.12%-86.69%-54.63%
Return on Invested Capital (ROIC)
---173.27%-89.13%
Gross Margin
--85.46%89.63%
Net Margin
---1011.75%-2825.7%
Debt / Equity
-0.12x0.12x0.06x
FCF Conversion
0.84x0.87x1.52x1.59x
Revenue Growth
----51.68%
Related:ALMS Dividend History·ALMS Revenue History·ALMS Price History·ALMS P/E History·ALMS Financial Ratios·ALMS Institutional Holders

ALMS SEC Filings & Documents

Alumis Inc. Common Stock (ALMS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 14, 2026·SEC

Material company update

Mar 30, 2026·SEC

Material company update

Mar 19, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 19, 2026·SEC

FY 2025

Mar 19, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

May 14, 2026·SEC

FY 2025

Nov 13, 2025·SEC

FY 2025

Aug 13, 2025·SEC

ALMS Frequently Asked Questions

Alumis Inc. Common Stock (ALMS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Alumis Inc. Common Stock (ALMS) reported $8.4M in revenue for fiscal year 2025.

Alumis Inc. Common Stock (ALMS) grew revenue by 0.0% over the past year. Growth has been modest.

Alumis Inc. Common Stock (ALMS) reported a net loss of $237.4M for fiscal year 2025.

Dividend & Returns

Alumis Inc. Common Stock (ALMS) has a return on equity (ROE) of -86.7%. Negative ROE indicates the company is unprofitable.

Alumis Inc. Common Stock (ALMS) had negative free cash flow of $377.0M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in ALMS back in 2022?

Total return calculator · dividends reinvested · 4+ years of data

See returns →

How much would $100/month in ALMS be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →